Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926514 | 0.88 | CNR1 (0.54) | POLBKMT2ALMNASMN1; SMN2CNR1 | |
| SCHEMBL9926577 | 0.76 | RAB9A (0.59) | KMT2AALDH1A1 | |
| SCHEMBL9926646 | 0.74 | P2RX7 (0.48) | KMT2ANPSR1 | |
| SCHEMBL30553808 | 0.74 | SMN1; SMN2 (0.55) | POLBKMT2AALDH1A1HTR1AMAOA | |
| SCHEMBL20772427 | 0.74 | SMN1; SMN2 (0.55) | POLBKMT2AALDH1A1HTR1AMAOA | |
| SCHEMBL23778710 | 0.74 | POLB (0.54) | POLBKMT2AALDH1A1HTR1AMAOA | |
| SCHEMBL4243681 | 0.74 | CYP2A13 (0.71) | KMT2ALMNANPSR1TSHR | |
| SCHEMBL9926585 | 0.74 | P2RX7 (0.50) | POLBKMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1578481 | 0.73 | EPHX2 (0.51) | POLBKMT2AALDH1A1HTR1AMAOA | |
| SCHEMBL11486045 | 0.73 | HTT (0.80) | KMT2AALDH1A1HTR1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | POLB 2312/4885KMT2A 1512/4885ALDH1A1 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.